Neola Medical (NEOLA) Q1 2025 earnings summary

Executive summary

• Received regulatory approval to initiate first clinical pilot study on preterm babies in Sweden, with first patient enrolled.

• Strengthened financial position via SEK 20 million directed share issue, adding institutional investors Cicero Fonder and Adrigo Fonder.

• Expanded IP portfolio with new patent grants in China and Europe for core lung monitoring technology.

• Named finalist for Sweden's Pioneer Prize at World Expo 2025, highlighting international innovation recognition.

Financial highlights

• Operating income for Q1 2025: SEK 2,162k (Q1 2024: SEK 3,448k), mainly from capitalized development work.

• Operating result: SEK -2,712k (Q1 2024: SEK -2,568k); result per share: SEK -0.04 (Q1 2024: SEK -0.04).

• Cash flow for the period: SEK 13,110k (Q1 2024: SEK 13,568k); cash and cash equivalents at period end: SEK 32,665k.

• Equity ratio at 95% (Q1 2024: 92%); no interest-bearing debt.

• Share capital increased to SEK 5,567,896.30 with 77,950,234 shares after new issue.

Outlook and guidance

• Preparing for pivotal clinical study in the U.S. to support planned FDA application for market approval.

• Aims for FDA and CE mark submissions in 2026, with approvals expected in 2026/2027.

• Financial goal to achieve positive operating profit three years after commercial launch.